Skip to main content
SpringerLink
Log in

Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Multi-gene assays have emerged as crucial tools for risk stratification in early-stage breast cancer. This study aimed to evaluate the prognostic significance of the 21-gene recurrence score (RS) in Chinese patients with pN0-1, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer. Among 800 patients recruited between 2009 and 2016, the median RS was 24 (0–69), with 27.4%, 46.8%, and 25.9% patients classified into low-, intermediate-, and high-risk groups. Cox regression analysis demonstrated that the high-risk category was associated with significantly higher odds of invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) events compared with the low-risk category (IDFS: HR = 2.450, 95% CI 1.017–5.902, P = 0.046; DDFS: HR = 2.829, 95% CI 1.013–7.901, P = 0.047). No significant association between RS category and overall survival (OS) was found (intermediate vs. low: HR= 1.244, 95% CI 0.292–5.297, P = 0.768; high vs. low: HR = 2.933, 95% CI 0.759–11.327, P = 0.119). RS, as a continuous variable, was a highly significant predictor for IDFS (HR= 1.028, 95% CI 1.010–1.047, P = 0.002), DDFS (HR= 1.030, 95% CI 1.010–1.051, P = 0.003), and OS (HR= 1.034, 95% CI 1.007–1.063, P = 0.014). Our findings suggested that RS may predict IDFS in Chinese patients with ER+/HER2− breast cancer with N0 or N1 disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27): 2817–2826

    Article  CAS  Google Scholar 

  2. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24(23): 3726–3734

    Article  CAS  Google Scholar 

  3. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF; Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010; 11(1): 55–65

    Article  CAS  Google Scholar 

  4. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373(21): 2005–2014

    Article  CAS  Google Scholar 

  5. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018; 379(2): 111–121

    Article  CAS  Google Scholar 

  6. Hornberger J, Alvarado MD, Rebecca C, Gutierrez HR, Yu TM, Gradishar WJ. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. J Natl Cancer Inst 2012; 104(14): 1068–1079

    Article  Google Scholar 

  7. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34(10): 1134–1150

    Article  CAS  Google Scholar 

  8. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017; André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti J, Garber V, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne O, Pagani KC, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 2017; 28(8): 1700–1712

    CAS  PubMed  Google Scholar 

  9. Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR. AJCC Cancer Staging Manual. New York: Springer International Publishing, 2017

    Book  Google Scholar 

  10. Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, Bordeleau L, Pritchard KI. Prospective evaluation of the 21-gene recurrence score assay for breast cancer decision-making in ontario. J Clin Oncol 2016; 34(10): 1065–1071

    Article  CAS  Google Scholar 

  11. Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, Untch S, Treece T, Blumencranz L, Soliman H. Association of 70-gene signature assay findings with physicians’ treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assay. JAMA Oncol 2018; 4(1): e173470

    Article  Google Scholar 

  12. Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011; 103(22): 1656–1664

    Article  CAS  Google Scholar 

  13. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31(31): 3997–4013

    Article  Google Scholar 

  14. Wu J, Fang Y, Lin L, Fei X, Gao W, Zhu S, Zong Y, Chen X, Huang O, He J, Zhu L, Chen W, Li Y, Shen K. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Oncotarget 2017; 8(24): 38706–38716

    Article  Google Scholar 

  15. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25(15): 2127–2132

    Article  Google Scholar 

  16. Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008; 26(25): 4063–4071

    Article  Google Scholar 

  17. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jr, Deshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R, Roter D. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001; 93(13): 979–989

    Article  CAS  Google Scholar 

  18. Carlson RW, Edge SB, Theriault RL; NCCN Breast Cancer Practice Guidelines Panel. NCCN: breast cancer. Cancer Control 2001; 8(6 Suppl 2): 54–61

    CAS  PubMed  Google Scholar 

  19. Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008; 26(5): 721–728

    Article  Google Scholar 

  20. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 2017; 377(19): 1836–1846

    Article  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Dr. Lin Lin, Dr. Xiaochun Fei, Dr. Jin Hong, Dr. Yan Fang, Dr. Wei Cao, and Dr. Caijin Lin for their invaluable assistance in this study. This work was supported by grants from the Technology Innovation Act Plan of Shanghai Municipal Science and Technology Commission (Nos. 14411-950200 and 14411950201), the National Natural Science Foundation of China (No. 81772797), and the Shanghai Municipal Commission of Health and Family Planning (No. 201840323). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Author notes

  1. These authors have contributed equally to this work.

Authors and Affiliations

  1. Comprehensive Breast Health Center, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Jiayi Wu, Weiqi Gao, Xiaosong Chen, Chunxiao Fei, Lin Lin, Weiguo Chen, Ou Huang, Siji Zhu, Jianrong He, Yafen Li, Li Zhu & Kunwei Shen

Authors
  1. Jiayi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Weiqi Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaosong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chunxiao Fei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lin Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Weiguo Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ou Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Siji Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jianrong He
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yafen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Li Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kunwei Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kunwei Shen.

Additional information

Compliance with ethics guidelines

Jiayi Wu, Weiqi Gao, Xiaosong Chen, Chunxiao Fei, Lin Lin, Weiguo Chen, Ou Huang, Siji Zhu, Jianrong He, Yafen Li, Li Zhu, and Kunwei Shen declare no conflicts of interest in this work. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study. Our study concerned patient’s tumor samples, clinical and pathological characteristics, adjuvant treatment, and the following data. Tumor samples and the following data were collected with written informed consent from patients. The treatment recommendations of the enrolled patients were not affected by the results of this study.

Electronic Supplementary Material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, J., Gao, W., Chen, X. et al. Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients. Front. Med. 15, 621–628 (2021). https://doi.org/10.1007/s11684-020-0738-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-020-0738-0

Keywords

Search

Navigation